Answers are grounded in this paper and cite their sources.
Use of H(2) blockers in general is not associated with an increased risk of breast cancer, although current use of ranitidine may increase risk of hormone receptor-positive ductal carcinoma. Further studies to confirm this finding are warranted.
No takes yet. Share an insight, caveat, or question.
Mathes et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: